Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial. (BICS)

Seonaidh Cotton, Graham Devereux* (Corresponding Author), Hassan Abbas, Andrew H Briggs, Karen Campbell, Rekha Chaudhuri, Gourab Choudhury, Dana Dawson, Anthony De Soyza, Shona Fielding, Simon Gompertz, John Haughney, Chim C Lang, Amanda Lee, Graeme MacLennan, William MacNee, Kirsty McCormack, Nicola McMeekin, Nicholas L Mills, Alyn MoriceJohn Norrie, Linda Petrie, David Price, Philip Short, Jørgen Vestbo, Paul Walker, Jadwiga A Wedzicha, Andrew Wilson, Brian J Lipworth

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta-blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consistently report that beta5 blocker use in people with COPD is associated with a reduced risk of COPD exacerbations.
The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-effective benefits. A sub-study will risk stratify participants for heart failure to investigate whether any beneficial effect of bisoprolol is restricted to those with unrecognised heart disease.

Methods: BICS is a pragmatic randomised parallel group double-blind placebo-controlled trial conducted in UK primary and secondary care sites. The major inclusion criteria are an established predominant respiratory diagnosis of COPD (post-bronchodilator FEV1<80% predicted, FEV1/FVC<0.7), a self-reported history of ≥2 exacerbations requiring treatment with antibiotics and/or oral corticosteroids in a 12-month period since March 2019, age ≥40 years and a smoking history ≥10 pack years. A computerised randomisation system will allocate 1574 participants with equal probability to intervention or control groups, stratified by centre, and recruitment in primary/secondary care. The intervention is bisoprolol (1.25 mg tablets) or identical placebo. The dose of bisoprolol/placebo is titrated up to a maximum of 4 tablets a day (5mg bisoprolol) over four-seven weeks depending on tolerance to up-dosing of bisoprolol/placebo – these titration assessments are completed by telephone or video call.
Participants complete the remainder of the 52-week treatment period on the final titrated dose (1,2,3,4 tablets) and during that time are followed up at 26 and 52 weeks by telephone or video call. The primary outcome is the total number of participant reported COPD exacerbations requiring oral corticosteroids and/or antibiotics during the 52-week treatment period. A sub-study will risk stratify participants for heart failure by echocardiography and
measurement of blood biomarkers.

Discussion: The demonstration that bisoprolol reduces the incidence of exacerbations would be relevant not only to patients and clinicians but also to healthcare providers, in the UK and globally.
Original languageEnglish
Article number307
Number of pages16
JournalTrials
Volume23
Issue number1
Early online date14 Apr 2022
DOIs
Publication statusPublished - 14 Apr 2022

Keywords

  • COPD
  • exacerbation
  • randomised controlled trial
  • bisoprol
  • beta blocker

Fingerprint

Dive into the research topics of 'Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial. (BICS)'. Together they form a unique fingerprint.

Cite this